A COMPARATIVE EXPECTED VALUE ANALYSIS STUDY TO DETERMINE IF THE ECONOMIC BENEFITS OF THE MOST COMMONLY PRESCRIBED PRESCRIPTION AND NON-PRESCRIPTION DRUGS IN THE UNITED STATES PROVIDE ECONOMIC VALUE | Zendy

S. Eric Anderson | Zendy

Open Access

A COMPARATIVE EXPECTED VALUE ANALYSIS STUDY TO DETERMINE IF THE ECONOMIC BENEFITS OF THE MOST COMMONLY PRESCRIBED PRESCRIPTION AND NON-PRESCRIPTION DRUGS IN THE UNITED STATES PROVIDE ECONOMIC VALUE

Author(s) -

S. Eric Anderson

Publication year - 2021

Publication title -

account and financial management journal

Language(s) - English

Resource type - Journals

ISSN - 2456-3374

DOI - 10.47191/afmj/v6i10.02

Subject(s) - medical prescription , pill , medicine , value (mathematics) , aspirin , clopidogrel , diabetes mellitus , economic analysis , depression (economics) , intensive care medicine , pharmacology , economics , agricultural economics , macroeconomics , endocrinology , machine learning , computer science

It was found that anti-biotics, aspirin, bisphosphonates, blood pressure lowering medications, statins, medications treating depression, diabetes, sexual dysfunction and the poly-pill provided economic value, while medications to treat Alzheimer’s, cancer, multiple sclerosis and Clopidogrel were not found to have provided economic value. The current evidence is insufficient to determine if weight loss medication provides economic value or not

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research